Friday, December 4, 2020

COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy

COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy In a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.

from Moneycontrol Business News https://ift.tt/2JAEliD
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Bajaj Auto shares fall 2% as firm, subsidiary fall prey to ransomware attack

Bajaj Auto shares dipped 2% following a ransomware attack on its systems and subsidiary, Bajaj Auto Technology Ltd, on June 23, 2026. The co...